These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 30245692)

  • 21. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions.
    Falcón-Beas C; Tittarelli A; Mora-Bau G; Tempio F; Pérez C; Hevia D; Behrens C; Flores I; Falcón-Beas F; Garrido P; Ascui G; Pereda C; González FE; Salazar-Onfray F; López MN
    Immunobiology; 2019 Sep; 224(5):697-705. PubMed ID: 31221438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased PD-1 Expression and Altered T Cell Repertoire Diversity Predict Mortality in Patients with Septic Shock: A Preliminary Study.
    Tomino A; Tsuda M; Aoki R; Kajita Y; Hashiba M; Terajima T; Kano H; Takeyama N
    PLoS One; 2017; 12(1):e0169653. PubMed ID: 28072859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Response of Live-Attenuated,
    Hassan R; Alley E; Kindler H; Antonia S; Jahan T; Honarmand S; Nair N; Whiting CC; Enstrom A; Lemmens E; Tsujikawa T; Kumar S; Choe G; Thomas A; McDougall K; Murphy AL; Jaffee E; Coussens LM; Brockstedt DG
    Clin Cancer Res; 2019 Oct; 25(19):5787-5798. PubMed ID: 31263030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.
    Chang AE; Redman BG; Whitfield JR; Nickoloff BJ; Braun TM; Lee PP; Geiger JD; Mulé JJ
    Clin Cancer Res; 2002 Apr; 8(4):1021-32. PubMed ID: 11948109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I Trial of Intratumoral Injection of
    Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
    Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
    [No Abstract]   [Full Text] [Related]  

  • 27. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.
    Hegmans JP; Hemmes A; Aerts JG; Hoogsteden HC; Lambrecht BN
    Am J Respir Crit Care Med; 2005 May; 171(10):1168-77. PubMed ID: 15764728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.
    Ebstein F; Sapede C; Royer PJ; Marcq M; Ligeza-Poisson C; Barbieux I; Cellerin L; Dabouis G; Grégoire M
    Am J Respir Crit Care Med; 2004 Jun; 169(12):1322-30. PubMed ID: 15070823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells.
    Parajuli P; Mathupala S; Sloan AE
    Neurosurgery; 2004 Nov; 55(5):1194-204. PubMed ID: 15509326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
    Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z
    Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ICOS
    Nagase H; Takeoka T; Urakawa S; Morimoto-Okazawa A; Kawashima A; Iwahori K; Takiguchi S; Nishikawa H; Sato E; Sakaguchi S; Mori M; Doki Y; Wada H
    Int J Cancer; 2017 Feb; 140(3):686-695. PubMed ID: 27756099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model.
    Lui KS; Ye Z; Chan HC; Tanaka Y; Cheung AKL
    Front Immunol; 2023; 14():1282710. PubMed ID: 38077396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lymphocyte activation markers in patients with ovarian cancer].
    Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
    Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
    Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    De La Maza L; Wu M; Wu L; Yun H; Zhao Y; Cattral M; McCart A; Cho BJ; de Perrot M
    Clin Cancer Res; 2017 Sep; 23(18):5502-5513. PubMed ID: 28606922
    [No Abstract]   [Full Text] [Related]  

  • 38. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
    Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
    J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma.
    Vroman H; Balzaretti G; Belderbos RA; Klarenbeek PL; van Nimwegen M; Bezemer K; Cornelissen R; Niewold ITG; van Schaik BD; van Kampen AH; Aerts JGJV; de Vries N; Hendriks RW
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.